GNI Ltd is focuses on the discovery and development of drugs that combat inflammation diseases and cancer. Liver, kidney fibrosis and lunch cancer are particularly common in Asia resulting in severe morbidity and mortality.
With our combination of gene-network research capabilities in Japan and our modern wet-lab research facilities in China, we have a significant cost advantage over the United States and Europe for drug development